The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
Open accessAbstract
Carbapenemase-producing Klebsiella pneumoniae strains (CP-Kps) are currently among the most important nosocomial pathogens. An observational study was conducted during 2009 to 2010 in two hospitals located in a high-prevalence area (Athens, Greece). The aims were (i) to evaluate the clinical outcome of patients with CP-Kp bloodstream infections (BSIs), (ii) to identify predictors of mortality, and (iii) to evaluate the various antibiotic schemes employed. A total of 205 patients with CP-Kp BSIs were identified: 163 (79.5%) were infected with KPC or KPC and VIM, and 42 were infected with VIM producers. For definitive treatment, 103 patients received combination therapy (two or more active drugs), 72 received monotherapy (one active drug), and 12 received therapy with no active drug. The remaining 18 patients died within 48 h after the onset of bacteremia. The all-cause 28-day mortality was 40%. A significantly higher mortality rate was observed in patients treated with monotherapy than in those treated with combination therapy (44.4% versus 27.2%; P = 0.018). The lowest mortality rate (19.3%) was observed in patients treated with carbapenem-containing combinations. In the Cox proportion hazards model, ultimately fatal disease (hazards ratio [HR], 3.25; 95% confidence interval [CI], 1.51 to 7.03; P = 0.003), the presence of rapidly fatal underlying diseases (HR, 4.20; 95% CI, 2.19 to 8.08; P < 0.001), and septic shock (HR, 2.15; 95% CI, 1.16 to 3.96; P = 0.015) were independent predictors of death. Combination therapy was strongly associated with survival (HR of death for monotherapy versus combination, 2.08; 95% CI, 1.23 to 3.51; P = 0.006), mostly due to the effectiveness of the carbapenem-containing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Horan, T. C., Andrus, M., & Dudeck, M. A. (2008) · American Journal of Infection Control · doi:10.1016/j.ajic.2008.03.002 · Cited by 6,626
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
Friedman, N. D., Kaye, K. S., Stout, J. E., McGarry, S. A., Trivette, S. L., Briggs, J. P., Lamm, W., Clark, C., MacFarquhar, J., Walton, A. L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-10-200211190-00007 · Cited by 1,668
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Self-citationTzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Self-citationTumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Patel, G., Huprikar, S., Factor, S. H., Jenkins, S. G., & Calfee, D. P. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/592412 · Cited by 836
Schwaber, M. J., & Carmeli, Y. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm318 · Cited by 626
Qureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06268-11 · Cited by 559
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Self-citationTsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Self-citationCarbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance
Pitout, J. D. D., Nordmann, P., & Poirel, L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01019-15 · Cited by 852
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Lee, C.-R., Lee, J. H., Park, K. S., Kim, Y. B., Jeong, B. C., & Lee, S. H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00895 · Cited by 739
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Update on the antibiotic resistance crisis
Rossolini, G. M., Arena, F., Pecile, P., & Pollini, S. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.09.006 · Cited by 695
Paul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y. D., Skiada, A., Andini, R., Eliakim-Raz, N., Nutman, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30099-9 · Cited by 623
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00080 · Cited by 520
Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P.-R., Viale, P., Paño-Pardo, J. R., Venditti, M., Tumbarello, M., Daikos, G., Cantón, R., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30228-1 · Cited by 512
Self-citationTumbarello, M., Trecarichi, E. M., De Rosa, F. G., Giannella, M., Giacobbe, D. R., Bassetti, M., Losito, A. R., Bartoletti, M., Del Bono, V., Corcione, S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv086 · Cited by 511
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 495
Shields, R. K., Chen, L., Cheng, S., Chavda, K. D., Press, E. G., Snyder, A., Pandey, R., Doi, Y., Kreiswirth, B. N., Nguyen, M. H., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02097-16 · Cited by 484
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
Self-citationZhang, Y., Wang, Q., Yin, Y., Chen, H., Jin, L., Gu, B., Xie, L., Yang, C., Ma, X., Li, H., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01882-17 · Cited by 450
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 435
Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?
Exner, M., Bhattacharya, S., Christiansen, B., Gebel, J., Goroncy‐Bermes, P., Hartemann, P., Heeg, P., Ilschner, C., Krämer, A., Larson, E., et al. (2017) · PubMed · doi:10.3205/dgkh000290 · Cited by 429
Tamma, P. D., Goodman, K. E., Harris, A. D., Tekle, T., Roberts, A., Taiwo, A., & Simner, P. J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw741 · Cited by 402
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
Jean, S.-S., Harnod, D., & Hsueh, P.-R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.823684 · Cited by 366
Tumbarello, M., Trecarichi, E. M., Corona, A., De Rosa, F. G., Bassetti, M., Mussini, C., Menichetti, F., Viscoli, C., Campoli, C., Venditti, M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy492 · Cited by 354
Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections
Suay-García, B., & Pérez-Gracia, M. T. (2019) · Antibiotics · doi:10.3390/antibiotics8030122 · Cited by 344
Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview
Vivas, R., Barbosa, A. A. T., Dolabela, S. S., & Jain, S. (2019) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0319 · Cited by 343
Treating infections caused by carbapenemase-producing Enterobacteriaceae
Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M., & Daikos, G. L. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12697 · Cited by 337
Self-citationHawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Treatment of Infections Due to MDR Gram-Negative Bacteria
Bassetti, M., Peghin, M., Vena, A., & Giacobbe, D. R. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00074 · Cited by 326
Boyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00397-20 · Cited by 315
Antibiotic strategies in the era of multidrug resistance
Karam, G., Chastre, J., Wilcox, M. H., & Vincent, J.-L. (2016) · Critical Care · doi:10.1186/s13054-016-1320-7 · Cited by 296
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Kreiswirth, B. N., & Clancy, C. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02497-17 · Cited by 289
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00151 · Cited by 288
Tumbarello, M., Raffaelli, F., Giannella, M., Mantengoli, E., Mularoni, A., Venditti, M., De Rosa, F. G., Sarmati, L., Bassetti, M., Brindicci, G., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab176 · Cited by 275
Rationalizing antimicrobial therapy in the ICU: a narrative review
Timsit, J.-F., Bassetti, M., Cremer, O., Daikos, G., de Waele, J., Kallil, A., Kipnis, E., Kollef, M., Laupland, K., Paiva, J.-A., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05520-5 · Cited by 266
Self-citationManagement of carbapenem-resistant Enterobacteriaceae infections
Durante-Mangoni, E., Andini, R., & Zampino, R. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.013 · Cited by 261
Carbapenemase-Producing Enterobacteriaceae
Paterson, D., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0035-1544208 · Cited by 257
Escalating antimicrobial resistance among Enterobacteriaceae: Focus on carbapenemases
Lynch, J. P., Clark, N. M., & Zhanel, G. G. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1904891 · Cited by 58
Metadata
- Authors
- Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., Georgiadou, S., Markogiannakis, A., Goukos, D., & Skoutelis, A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-04
- Volume
- 58
- Issue
- 4
- Pages
- 2322-2328
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2042164350
- Cited by
- 597
- References
- 24
- FWCI
- 28.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.